Cite
HARVARD Citation
Vinitsky, A. et al. (n.d.). LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). Neuro-oncology. p. i92. [Online].